Enantiocomplementary Michael Additions of Acetaldehyde to Aliphatic Nitroalkenes Catalyzed by Proline-Based Carboligases

Andreas Kunzendorf,* [a] Mohammad Saifuddin,* [a, b] and Gerrit J. Poelarends* [a]

The blockbuster drug Pregabalin is widely prescribed for the treatment of painful diabetic neuropathy. Given the continuous epidemic growth of diabetes, the development of sustainable synthesis routes for Pregabalin and structurally related pharmaceuticals, such as Pregabalin (anticonvulsant, Scheme 1), Rolipram (antidepressant) or Baclofen (muscle relaxant) is of high interest. Enantioenriched γ-nitroaldehydes are versatile synthons for the production of GABA derivatives, which can be prepared through a Michael-type addition of acetaldehyde to \( \alpha \beta \gamma \) unsaturated nitroalkenes. Here we report that tailored \( \alpha \beta \gamma \) variants of the promiscuous enzyme 4-oxalocrotonate tautomerase (4-OT) can accept diverse aliphatic \( \alpha \beta \gamma \)-unsaturated nitroalkenes as substrates for acetaldehyde addition. Highly enantioenriched aliphatic (R)- and (S)-\( \gamma \)-nitroaldehydes were obtained in good yields using two enantiocomplementary 4-OT variants. Our results underscore the synthetic potential of 4-OT for the preparation of structurally diverse synthons for bioactive analogues of Pregabalin.

Introduction

Chiral \( \gamma \)-nitroaldehydes are versatile building blocks for \( \gamma \)-amino butyric acid (GABA, Scheme 1) derivatives that have broad application as pharmaceuticals, such as Pregabalin (anticonvulsant, Scheme 1), Rolipram (antidepressant) or Baclofen (muscle relaxant). The blockbuster drug Pregabalin is widely prescribed for the treatment of painful diabetic neuropathy, and with the continuous epidemic growth of diabetes, the development of efficient and sustainable synthesis routes for Pregabalin and structurally related pharmaceutically active GABA derivatives is of high academic and industrial interest. The addition of acetaldehyde to \( \alpha \beta \gamma \)-unsaturated nitroalkenes offers convenient access to \( \gamma \)-nitroaldehydes from which the respective GABA derivatives can be obtained in two simple chemical steps. Consequently, extensive research has been focused on the asymmetric synthesis of \( \gamma \)-nitroaldehydes mainly through using proline-derived organocatalysts or small peptides. We reported that the enzyme 4-oxalocrotonate tautomerase (4-OT) is able to promiscuously catalyze the addition of acetaldehyde to several \( \alpha \beta \gamma \)-unsaturated nitroalkenes, yielding the corresponding \( \gamma \)-nitroaldehydes with excellent enantioselectivity. In contrast, only one aliphatic \( \alpha \beta \gamma \)-unsaturated nitroalkene as substrate for this 4-OT catalyzed reaction has been reported, yielding the \( \gamma \)-nitroaldehyde precursor for Pregabalin. Structural analogues of Pregabalin...
show a diverse effect on biological activity, which emphasizes the importance of developing efficient synthetic strategies for related aliphatic GABA derivatives and their precursors. In this study, we therefore focused on further expanding the substrate scope of the enantiocomplementary 4-OT variants L8Y/M45Y/F50A and A33D towards aliphatic α,β-unsaturated nitroalkenes as Michael acceptors, enabling the asymmetric synthesis of various linear, branched and cyclic aliphatic γ-nitroaldehydes.

**Results and Discussion**

We started our investigation by preparing a set of aliphatic α,β-unsaturated nitroalkenes (2b-f, 2h) with different alkyl substitutions connected to the carbon-carbon double bond, either by a nitration of olefins 4 with 'BuONO and TEMPO or by a Henry reaction, followed by dehydration, between aldehydes 5 and nitromethane 6 (Scheme 2, see Supporting Information for details).
The chemically prepared nitroalkenes 2b–f, 2h, as well as commercially available 2g, were then tested as potential Michael acceptors in acetaldehyde (1) additions catalyzed by 4-OT variant A33D or L8Y/M45Y/F50A. To prevent undesired non-enzymatic water addition to the \( \alpha,\beta \)-unsaturated nitroalkenes, the reactions for the addition of 1 (150 mM) to 2b–h (3 mM) were performed in sodium phosphate buffer at pH 6.5 and with suitable biocatalyst loading (100 \( \mu \)M) to shorten reaction times.\(^{[21]}\) Up to 15% ethanol was used as a cosolvent to solubilize the relatively apolar aliphatic \( \alpha,\beta \)-unsaturated nitroalkenes 2b–h. Previous experiments indicated that ethanol, in contrast to other cosolvents such as DMSO, has no negative effect on the stereoselectivity of 4-OT.\(^{[16]}\) The progress of the semi-preparative scale reactions was followed by UV spectroscopy until the decrease in absorbance at \( \lambda = 250 \) nm indicated completion of the reactions. The reaction times for the conversion of 2b–f ranged from < 0.5 h to 2.5 h.

Gratifyingly, both 4-OT variants readily accepted \( \alpha,\beta \)-unsaturated nitroalkenes 2b–f as non-native substrates to give the corresponding \( \gamma \)-nitroaldehydes products 3b–f in good to excellent yields (46%–92%, Figure 2, see Supporting Information Figures S1–32). The sterically more demanding nitroalkenes 2g,h were not accepted as substrates (< 1% conversion after 2.5 h reaction time). Thus, both 4-OT variants accept linear, branched and cyclic aliphatic \( \alpha,\beta \)-unsaturated nitroalkenes as acceptors for the Michael-type addition of 1.

The enantiomeric ratio and absolute configuration of the products were determined by chiral-phase GC analysis using chemically prepared racemic 3b–f as reference compounds. Analysis of the products showed that variants 4-OT A33D and 4-OT L8Y/M45Y/F50A afford the respective enantiomers of 3b–f with excellent enantiopurity (e.r. up to > 99:1, see Supporting Information Figures S1–32). For products 3c,f the absolute configuration was determined by comparison with previously reported literature data.\(^{[6,7]}\) Variant 4-OT A33D exclusively yielded the (R)-enantiomer of compound 3c and the (S)-enantiomer of product 3f (same geometry but different priority of the substituents at the chiral center). Indeed, variant 4-OT L8Y/M45Y/F50A afforded exclusively the opposite enantiomers, that is (S)-3c and (R)-3f. For products 3b,d,e the absolute configuration was not determined, but again opposite enantiomers were produced by 4-OT A33D and 4-OT L8Y/M45Y/F50A. Thus, convenient enantiocomplementary synthesis of the (R)- and (S)-enantiomers of 3b–f can be achieved by using these tailor-made 4-OT variants. Pleasingly, the stereopreference and high enantioselectivity of both 4-OT variants, as previously observed with aromatic compounds, is also witnessed with the aliphatic substrates. Taken together, these results demonstrate an attractive biocatalytic approach for the asymmetric synthesis of highly enantioenriched synthons for pharmaceutically active aliphatic GABA derivatives.

### Conclusion

In conclusion, we have explored the substrate scope of two previously engineered 4-OT variants\(^{[16]}\) using a focused set of linear, branched, and cyclic aliphatic \( \alpha,\beta \)-unsaturated nitroalkenes. Biocatalytic reactions using acetaldehyde 1 as a substrate are scarce and often face challenges due to the high inherent reactivity of 1.\(^{[19,20]}\) Pleasingly, the here presented 4-OT catalyzed Michael reactions with 1 as a nucleophile readily proceed under mild conditions in an environmentally friendly aqueous buffer system with ethanol as a green and sustainable cosolvent.\(^{[21]}\) In contrast to aromatic nitroalkenes,\(^{[22,23]}\) aliphatic nitroalkanes are prone to rapid non-enzymatic hydration. To outcompete this undesired hydration of the nitroalkanes 2a–h, we kept reaction times short by using a rather high catalyst loading as well as an excess of acetaldehyde 1. In comparison with previously reported procedures for the preparation of \( \gamma \)-nitroaldehydes using small-molecule aminocatalysts, the here presented enzymatic reactions proceed in environmentally benign aqueous solvent and use up to 6-times lower catalyst loading.\(^{[6,8]}\)

Both assessed 4-OT variants successfully catalyze the Michael-type addition of acetaldehyde 1 to several aliphatic \( \alpha,\beta \)-unsaturated nitroalkenes 2b–f yielding both enantiomers of the corresponding \( \gamma \)-nitroaldehydes 3b–f with good yields and excellent enantiopurity (e.r.: 98:2 to > 99:1). Notably, the products 3b–f are valuable precursors for the respective GABA derivatives, which show bioactivity as anticonvulsants in pharmacokinetic in vitro assays and animal studies.\(^{[24,25]}\)

Using previously developed chemoenzymatic cascade reactions, the prepared \( \gamma \)-nitroaldehydes can be readily converted in two steps into the respective GABA analogous.\(^{[16]}\) Together with our continued protein engineering efforts to improve 4-OT’s stability and activity,\(^{[26,27]}\) this work further highlights the potential of proline-based carboligases as powerful catalysts for abiological carbon-carbon bond-forming reactions.
Experimental Section

A detailed description of the experimental methods and product characterization can be found in the Supporting Information.

Acknowledgements

We acknowledge financial support from the Netherlands Organization of Scientific Research (VICI grant 724.016.002).
Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

Keywords: biocatalysis · enamine catalysis · enzyme catalysis · Michael addition · nitroaldehydes

[1] T. R. Bellotti, T. Capiris, I. V. Ekhato, J. J. Kinsora, M. J. Field, T. G. Heffner, L. T. Meltzer, J. B. Schwarz, C. P. Taylor, A. J. Thorpe, M. G. Vartanian, L. D. Wise, T. Zhi-Su, M. L. Weber, D. J. Wustrow, L. T. Meltzer, J. B. Schwarz, C. P. Taylor, A. J. Thorpe, M. G. Vartanian, https://doi.org/10.1002/cbic.202100644

Manuscript received: November 20, 2021
Revised manuscript received: January 19, 2022
Accepted manuscript online: January 20, 2022
Version of record online: February 2, 2022

Research Article
doi.org/10.1002/cbic.202100644

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

Keywords: biocatalysis · enamine catalysis · enzyme catalysis · Michael addition · nitroaldehydes

[1] T. R. Bellotti, T. Capiris, I. V. Ekhato, J. J. Kinsora, M. J. Field, T. G. Heffner, L. T. Meltzer, J. B. Schwarz, C. P. Taylor, A. J. Thorpe, M. G. Vartanian, L. D. Wise, T. Zhi-Su, M. L. Weber, D. J. Wustrow, L. T. Meltzer, J. B. Schwarz, C. P. Taylor, A. J. Thorpe, M. G. Vartanian, https://doi.org/10.1002/cbic.202100644

Manuscript received: November 20, 2021
Revised manuscript received: January 19, 2022
Accepted manuscript online: January 20, 2022
Version of record online: February 2, 2022